Treatment of Stage 2 Hypertension

Classification and Immediate Action

A blood pressure of 190/80 mmHg is classified as stage 2 hypertension, which mandates immediate drug treatment without delay, according to the American Heart Association 1, 2
This level of blood pressure significantly increases cardiovascular risk and requires prompt intervention to reduce morbidity and mortality, as stated by the European Society of Cardiology 3

The American College of Cardiology recommends starting with two-drug combination therapy immediately, rather than monotherapy, as most patients with stage 2 hypertension require multiple agents to achieve blood pressure control 4, 5
For non-Black patients, the preferred initial combination is an ACE inhibitor or ARB plus a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic, as recommended by the American Heart Association 1, 2
For Black patients, the preferred initial combination is an ARB plus a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic, according to the European Society of Cardiology 1, 2
Single-pill combination formulations are strongly preferred to improve adherence and simplify the regimen, as stated by the European Heart Journal 1, 6
Increase to full doses of the initial two-drug combination if blood pressure target is not achieved within 1 month, as recommended by the American College of Cardiology 1, 3
If blood pressure remains uncontrolled with two drugs at full doses, escalate to a three-drug combination, preferably as a single-pill combination, according to the European Society of Cardiology 1, 6

The American Heart Association recommends a target blood pressure of <130/80 mmHg for most adults, with treatment aimed at achieving this within 3 months 1, 6, 3
For adults <65 years, a systolic blood pressure of 120-129 mmHg is optimal if well tolerated, as stated by the European Heart Journal 6
Aim to reduce blood pressure by at least 20/10 mmHg from baseline, according to the American College of Cardiology 1, 3

The European Society of Cardiology recommends implementing evidence-based lifestyle interventions immediately alongside pharmacotherapy, including weight reduction, dietary modifications, physical activity, alcohol limitation, and tobacco cessation 6
Target a BMI of 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women), as recommended by the European Heart Journal 6
Adopt a DASH or Mediterranean diet pattern with sodium restriction to <2,300 mg/day and increased potassium intake, according to the European Society of Cardiology 6
Engage in 150 minutes/week of moderate-intensity aerobic exercise plus resistance training 2-3 times/week, as stated by the European Heart Journal 6

Reassess blood pressure within 1 month after initiating therapy to evaluate response and adjust medications, as recommended by the American College of Cardiology 3
Achieve target blood pressure within 3 months of treatment initiation, according to the American Heart Association 1, 6
Consider home blood pressure monitoring or 24-hour ambulatory blood pressure monitoring to confirm office readings and detect white-coat or masked hypertension, as stated by the European Society of Cardiology 1, 2

Assess for secondary hypertension if blood pressure is difficult to control or patient is young (<40 years), particularly looking for renal artery stenosis, primary aldosteronism, pheochromocytoma, or obstructive sleep apnea, as recommended by the American College of Cardiology 3
Evaluate for target organ damage, including left ventricular hypertrophy, proteinuria/albuminuria, and renal function, according to the European Society of Cardiology 7, 3
Calculate cardiovascular risk, particularly for patients with diabetes, chronic kidney disease, or established cardiovascular disease, as stated by the American Heart Association 1, 8

The American College of Physicians recommends initiating two antihypertensive agents from different classes when blood pressure is more than 20 mmHg above systolic goal or 10 mmHg above diastolic goal 9, 10
Starting with combination therapy achieves blood pressure goals more rapidly and reduces cardiovascular events sooner 10

The American Heart Association recommends a thiazide-like diuretic (chlorthalidone preferred over hydrochlorothiazide) plus either an ACE inhibitor, ARB, or dihydropyridine calcium channel blocker, ideally as a single-pill combination 9
For non-Black patients, the first choice is a thiazide-like diuretic + ACE inhibitor, with alternatives being thiazide-like diuretic + ARB or thiazide-like diuretic + dihydropyridine calcium channel blocker 9
For Black patients, the first choice is a thiazide-like diuretic + dihydropyridine calcium channel blocker, as ACE inhibitors and ARBs are less effective at lowering blood pressure in Black patients when used as monotherapy 9

Chlorthalidone is preferred over hydrochlorothiazide because it lowers blood pressure more effectively, particularly at night, and has a longer therapeutic half-life 11
Chlorthalidone and indapamide have more cardiovascular disease risk reduction data than hydrochlorothiazide 11

Fixed-dose combinations produce greater blood pressure reduction at lower doses of component agents, resulting in fewer side effects 10
The target blood pressure is <130/80 mmHg for most adults 9

For patients with diabetes, ACE inhibitors or ARBs are recommended as first-line therapy in combination with a thiazide-like diuretic or calcium channel blocker, providing additional renal protection in diabetic patients with albuminuria 9, 12
For patients with coronary artery disease or chronic kidney disease, ACE inhibitors or ARBs should be included in the regimen, particularly if albuminuria is present 9, 12

A DASH or Mediterranean diet pattern is recommended alongside pharmacotherapy 12